- Home
- CALC vs COCH Comparison
CALC vs COCH Comparison
Compare CALC & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- COCH
- Stock Information
- Founded
- CALC 2011
- COCH 1995
- Country
- CALC United States
- COCH United States
- Employees
- CALC N/A
- COCH N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- COCH Blank Checks
- Sector
- CALC Health Care
- COCH Finance
- Exchange
- CALC Nasdaq
- COCH Nasdaq
- Market Cap
- CALC 48.1M
- COCH 25.2M
- IPO Year
- CALC N/A
- COCH N/A
- Fundamental
- Price
- CALC $2.72
- COCH $1.32
- Analyst Decision
- CALC Strong Buy
- COCH Strong Buy
- Analyst Count
- CALC 2
- COCH 2
- Target Price
- CALC $14.50
- COCH $9.25
- AVG Volume (30 Days)
- CALC 63.4K
- COCH 789.8K
- Earning Date
- CALC 11-12-2025
- COCH 11-13-2025
- Dividend Yield
- CALC N/A
- COCH N/A
- EPS Growth
- CALC N/A
- COCH N/A
- EPS
- CALC N/A
- COCH N/A
- Revenue
- CALC N/A
- COCH $222,000.00
- Revenue This Year
- CALC N/A
- COCH $4.27
- Revenue Next Year
- CALC N/A
- COCH $23.37
- P/E Ratio
- CALC N/A
- COCH N/A
- Revenue Growth
- CALC N/A
- COCH N/A
- 52 Week Low
- CALC $1.42
- COCH $1.06
- 52 Week High
- CALC $5.65
- COCH $3.99
- Technical
- Relative Strength Index (RSI)
- CALC 43.47
- COCH 49.38
- Support Level
- CALC $3.00
- COCH $1.23
- Resistance Level
- CALC $3.73
- COCH $1.37
- Average True Range (ATR)
- CALC 0.35
- COCH 0.09
- MACD
- CALC -0.01
- COCH 0.02
- Stochastic Oscillator
- CALC 9.01
- COCH 78.79
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.